Cyclopharm (ASX:CYC) Completes Capital Raising to Finance USA Commercialisation

  • January 25, 2021 02:04 PM AEDT
  • Hina Chowdhary
    Director, Equities Research Hina Chowdhary
    1706 Posts

    Hina Chowdhary is the Director, Equity Research at Kalkine and has an extensive experience of about 15 years in the area of Research, which includes 5+ years in Equities Research particularly.She has earned a Master of Science degree from the renowne...

Cyclopharm (ASX:CYC) Completes Capital Raising to Finance USA Commercialisation

Summary

  • Radiopharmaceutical company Cyclopharm completed A$30 million placement with overwhelming support from its institutional and sophisticated investors.
  • The Company is well-positioned for the rapid commercialisation in the US, after FDA approval.
  • The placement will support the expansion of the use of TechnegasTM beyond the pulmonary embolism market.
Gold MTF non-AMP

ASX-listed radiopharmaceutical player Cyclopharm Limited (ASX:CYC) has completed a share placement of almost 11.5 million new fully paid ordinary shares to institutional and sophisticated investors. The shares will be issued at a per-share price of A$2.60, raising A$30.0 million before costs. The Company notified that the Placement Shares are anticipated to be issued and commence trading on the ASX on 1 February 2021.

The placement obtained overwhelming support from institutional as well as sophisticated investors of Cyclopharm. The indicative plan for the SPP offer is represented below; however, CYC has rights to change the timetable without any prior notice.

Source: CYC ASX Update (25 January 2021)

Use of funds

Funds raised under the placement and associated Share Purchase Plan (SPP) will be used to finance activities related to the Company’s accelerated US market expansion. The market expansion will follow the expected FDA approval to market TechnegasTM.

In particular, the Company will utilise funds to build-up its TechnegasTM Generators assets. These assets would be used as part of the US rollout strategy using CYC’s new Service Model.

CYC notified that the capital raising would support rapid US commercialisation following the FDA approval. The FDA is anticipated to approve TechnegasTM in the second quarter of 2021.

Besides, these funds will support other strategic priorities, including:

  • Expansion of the use of TechnegasTM beyond the pulmonary embolism market such as COPD and Asthma.
  • Ongoing R&D activities.
  • Enhancement of product and systems.
  • Working capital
  • Some of the funds will be utilised to pay the costs of the offer.

Cyclopharm also notified that the US sales strategy would involve the generators’ placement without any capital cost to customers. Further, this will support rapid penetration in the US market, focusing on obtaining high margin recurring consumable revenue.  

Source: CYC presentation (25 January 2021)

Commenting on the Placement, Mr James McBrayer Managing Director Cyclopharm, said,

Outlook

 

Source: CYC presentation (25 January 2021)

Stock Information: On 25 January 2021, CYC shares were trading at A$2.940 at AEDT 2:01 PM, in line with the previous close. Cyclopharm’s market capitalisation stands at A$236 million.

 

 


Disclaimer
The website https://kalkinemedia.com/au is a service of Kalkine Media Pty. Ltd. (Kalkine Media) A.C.N. 629 651 672. The principal purpose of the content on this website is to provide factual information only and does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) or engage in any investment activity under discussion. We are neither licensed nor qualified to provide investment advice through this platform. In providing you with the content on this website, we have not considered your objectives, financial situation or needs. You should make your own enquiries and obtain your own independent advice prior to making any financial decisions.
Some of the images that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed on this website unless stated otherwise. The images that may be used on this website are taken from various sources on the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image. The information provided on the website is in good faith, however Kalkine Media does not make any representation or warranty regarding the content, accuracy, or use of the content on the website.

 

   
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK